Ignite Creation Date:
2024-05-05 @ 11:34 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00088530
Status:
COMPLETED
Last Update Posted:
2020-02-05
First Post:
2004-07-28
Brief Title:
BBR 2778 for Relapsed Aggressive Non-Hodgkins Lymphoma NHL
Sponsor:
CTI BioPharma
Organization:
CTI BioPharma
Study Overview
Official Title:
Pixantrone BBR 2778 Versus Other Chemotherapeutic Agents for Third-line Single Agent Treatment of Patients With Relapsed Aggressive Non-Hodgkins Lymphoma A Randomized Controlled Phase III Comparative Trial
Status:
COMPLETED
Status Verified Date:
2020-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
BBR 2778 is a novel aza-anthracenedione that has activity in experimental tumors and shows reduced potential for cardiotoxicity in animal models This cytotoxic agent has structural similarities with mitoxantrone as well as general similarities with anthracyclines such as the tricyclic central quinoid chromophore
Detailed Description:
The primary study objective is to compare the efficacy of BBR 2778 to a selection of single agents Secondary objectives are to compare the safety and tolerability of BBR 2778 to a selection of single agents and to assess the pharmacokinetic parameters of BBR 2778 in a subset of this patient population
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None